-+ 0.00%
-+ 0.00%
-+ 0.00%

Chardan Capital Maintains Buy on CRISPR Therapeutics, Raises Price Target to $76

Benzinga·02/17/2026 13:18:56
Listen to the news
Chardan Capital analyst Geulah Livshits maintains CRISPR Therapeutics (NASDAQ:CRSP) with a Buy and raises the price target from $74 to $76.